All In Biotech

NDA 216359 · Rafa Labs LTD

Midazolam Hydrochloride (Autoinjector)

Midazolam Hydrochloride · Intramuscular · Benzodiazepine

Priority review

Last checked: Nov 19, 2026Latest source record: May 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 8, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,448

153 Phase 3, 96 recruiting

FAERS reports

1,487

1,393 serious, 391 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation [see Warnings and Precautions (5.1), Drug Interactions (7.1)]. The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with a n increased frequency of serious adverse outcomes. Before prescribing Midazolam Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)]. The continued use of...

What it is approved for

From the label in effect Feb 18, 2026.

Midazolam Injection is indicated for the treatment of status epilepticus in adults. Midazolam Injection is a benzodiazepine indicated for the treatment of status epilepticus in adults. (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 8, 2022 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR) · MIDAZOLAM HYDROCHLORIDE EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML) · SOLUTION, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Midazolam" as an intervention, any sponsor and status, largest first.

All 1,448 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death346
  • therapy interrupted158
  • therapy cessation113
  • hospitalisation95
  • surgery72
  • condition aggravated53
  • pneumonia44
  • fall36
  • cerebrovascular accident31
  • covid-1931
  • infection25
  • pain25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
20051
20061
20092
20103
20122
20134
20146
20153
20164
201841
2019400
2020562
2021420
20226
20233
20244
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,612 on PubMed

Sponsor: Rafa Labs LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.